Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012144208 - DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ITM2A ANTIBODY

Publication Number WO/2012/144208
Publication Date 26.10.2012
International Application No. PCT/JP2012/002697
International Filing Date 18.04.2012
IPC
C07K 16/30 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07K 16/46 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/3061
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3061Blood cells
C07K 2317/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
C07K 2317/565
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
565Complementarity determining region [CDR]
Applicants
  • 国立大学法人東京大学 The University of Tokyo [JP]/[JP] (AllExceptUS)
  • 中外製薬株式会社 CHUGAI SEIYAKU KABUSHIKI KAISHA [JP]/[JP] (AllExceptUS)
  • 油谷 浩幸 ABURATANI, Hiroyuki [JP]/[JP] (UsOnly)
  • 石川 俊平 ISHIKAWA, Shumpei [JP]/[JP] (UsOnly)
  • 川合 重人 KAWAI, Shigeto [JP]/[JP] (UsOnly)
Inventors
  • 油谷 浩幸 ABURATANI, Hiroyuki
  • 石川 俊平 ISHIKAWA, Shumpei
  • 川合 重人 KAWAI, Shigeto
Agents
  • 大野 聖二 OHNO, Seiji
Priority Data
2011-09248818.04.2011JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ITM2A ANTIBODY
(FR) DIAGNOSTIC ET TRAITEMENT DU CANCER À L'AIDE D'UN ANTICORPS ANTI-ITM2A
(JA) 抗ITM2A抗体を用いる癌の診断および治療
Abstract
(EN) Disclosed is a monoclonal antibody capable of binding to ITM2A protein. The antibody is useful for the diagnosis, prevention and treatment of cancer such as Ewing sarcoma, T cell leukemia, T cell lymphoma, acute myelocytic leukemia, B cell tumor and multiple myeloma. Also provided are: a pharmaceutical composition, a cell proliferation inhibitor and an anti-cancer agent, each of which contains the antibody as an active ingredient; and a method for treating cancer, a method for predicting the success of a cancer therapy, and a method for determining the occurrence of cancer in a subject, each of which utilizes the antibody.
(FR) L'invention concerne un anticorps monoclonal apte à se lier à une protéine ITM2A. L'anticorps est utile pour le diagnostic, la prévention et le traitement du cancer, tel que le sarcome d'Ewing, la leucémie à lymphocytes T, le lymphome T, la leucémie myéloïde aigüe, une tumeur à lymphocytes B et un myélome multiple. L'invention concerne également : une composition pharmaceutique, un inhibiteur de prolifération cellulaire et un agent anticancéreux, chacun d'entre eux contenant l'anticorps comme principe actif ; et une méthode de traitement d'un cancer, un procédé de prédiction du succès d'une thérapie anticancéreuse, et un procédé de détermination de l'apparition d'un cancer chez un sujet, chacun d'entre eux utilisant l'anticorps.
(JA)  ITM2Aタンパク質に結合するモノクローナル抗体が開示される。この抗体は、ユーイング肉腫、T細胞性白血病、T細胞性リンパ腫、急性骨髄性白血病、B細胞腫瘍、多発性骨髄腫などの癌の診断、予防および治療に有用である。また、該抗体を有効成分として含有する医薬組成物、細胞増殖抑制剤、抗癌剤、および該抗体を用いて癌を治療する方法、癌治療の奏功性を予測する方法、および被験者における癌の存在を決定する方法も提供する。
Latest bibliographic data on file with the International Bureau